Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms

NCT00604825 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00604825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00604825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
July 17, 2007
Completion date
July 23, 2008
Enrollment
356 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

menopausal and female climacteric states